p53 mutations that reduce or abolish its function are closely associated with anticancer drug resistance in various cancers [15,16], whereas mutant p53 occurrence in ovarian cancer has no effect on apoptotic death induced by paclitaxel [17]. Here, TP53 is linked to ovarian carcinoma.